Algen is a platform therapeutics and drug discovery company using the world’s leading CRISPR and AI to uncover disease-driving RNA messages to find treatments for cancer, inflammation and other diseases. Spun out from Nobel Laureate Professor Jennifer Doudna's Lab, Algen aims to develop the world’s smartest drug discovery decision platform and data universe to create next-generation therapeutics. Algen has its internal drug development pipeline and partners with a number of leading pharmaceutical companies on its flagship next-generation CRISPR-based platform.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
Our proprietary flagship AlgenBrain Platform is commercialized and partnered. We have three drug programs in the pipeline, the lead asset is a development candidate in the preclinical stage.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):